Integrins and adhesion molecules as targets to treat inflammatory bowel disease

Current Opinion in Pharmacology

Volumn 25, Issue , 2015, Pages 67-71

  Bravatà, Ivana ^a   Allocca, Mariangela ^a   Fiorino, Gionata ^a   Danese, Silvio ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABRILUMAB; ADHESION MOLECULE ANTIBODY; AJM 300; CELL ADHESION MOLECULE; ETROLIZUMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PLACEBO; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERANCE; HUMAN; INFLAMMATORY BOWEL DISEASE; JC VIRUS; LOADING DRUG DOSE; MAINTENANCE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN TARGETING; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIREMIA; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; INFLAMMATORY BOWEL DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ADHESION MOLECULES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTEGRINS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84949483492     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.11.007     Document Type: Review

References (22)

1. L. Peyrin-Biroulet, P. Desreumaux, W.J. Sandborn, and J.F. Colombel Crohn's disease: beyond antagonists of tumour necrosis factor Lancet 372 2008 67 81
2. L. Peyrin-Biroulet, A. Cieza, W.J. Sandborn, M. Coenen, Y. Chowers, T. Hibi, N. Kostanjsek, G. Stucki, and J.F. Colombel Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health Gut 61 2012 241 247
3. L. Peyrin-Biroulet Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature Am J Gastroenterol 108 2013 859 860
4. M. Henriksen, J. Jahnsen, I. Lygren, J. Sauar, O. Kjellevold, T. Schulz, M.H. Vatn, and B. Moum Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study) Inflamm Bowel Dis 12 2006 543 550
5. W.J. Sandborn, G. van Assche, W. Reinisch, J.F. Colombel, G. D'Haens, D.C. Wolf, M. Kron, M.B. Tighe, A. Lazar, and R.B. Thakkar Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257-265 e 251-253
6. A.C. Ford, W.J. Sandborn, K.J. Khan, S.B. Hanauer, N.J. Talley, and P. Moayyedi Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 644 659 quiz 660
7. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W.J. Sandborn, and J.F. Colombel Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 2008 644 653
8. A. Amiot, and L. Peyrin-Biroulet Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases Therap Adv Gastroenterol 8 2015 66 82
9. I.C. Lawrance, G.L. Radford-Smith, P.A. Bampton, J.M. Andrews, P.K. Tan, A. Croft, R.B. Gearry, and T.H. Florin Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience J Gastroenterol Hepatol 25 2010 1732 1738
10. T. Lobaton, S. Vermeire, G. Van Assche, and P. Rutgeerts Review article: anti-adhesion therapies for inflammatory bowel disease Aliment Pharmacol Ther 39 2014 579 594
11. S. Brand Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease Gut 58 2009 1152 1167
12. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756 1767
13. S.R. Targan, B.G. Feagan, R.N. Fedorak, B.A. Lashner, R. Panaccione, D.H. Present, M.E. Spehlmann, P.J. Rutgeerts, Z. Tulassay, M. Volfova, and et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial Gastroenterology 132 2007 1672 1683
14. W.J. Sandborn, J.F. Colombel, R. Enns, B.G. Feagan, S.B. Hanauer, I.C. Lawrance, R. Panaccione, M. Sanders, S. Schreiber, S. Targan, and et al. Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 2005 1912 1925
15. B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J.F. Colombel, W.J. Sandborn, G. Van Assche, J. Axler, H.J. Kim, S. Danese, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
16. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, S. Hanauer, J.F. Colombel, B.E. Sands, M. Lukas, R.N. Fedorak, S. Lee, B. Bressler, and et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
17. B.E. Sands, B.G. Feagan, P. Rutgeerts, J.F. Colombel, W.J. Sandborn, R. Sy, G. D'Haens, S. Ben-Horin, J. Xu, M. Rosario, and et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 2014 618-627 e 613
18. E.G. Stefanich, D.M. Danilenko, H. Wang, S. O'Byrne, R. Erickson, T. Gelzleichter, H. Hiraragi, H. Chiu, S. Ivelja, S. Jeet, and et al. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes Br J Pharmacol 162 2011 1855 1870
19. P.J. Rutgeerts, R.N. Fedorak, D.W. Hommes, A. Sturm, D.C. Baumgart, B. Bressler, S. Schreiber, J.C. Mansfield, M. Williams, M. Tang, and et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis Gut 62 2013 1122 1130
20. S. Vermeire, S. O'Byrne, M. Keir, M. Williams, T.T. Lu, J.C. Mansfield, C.A. Lamb, B.G. Feagan, J. Panes, A. Salas, and et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial Lancet 384 2014 309 318
21. W.J. Pan, K. Kock, W.A. Rees, B.A. Sullivan, C.M. Evangelista, M. Yen, J.M. Andrews, G.L. Radford-Smith, P.J. Prince, K.O. Reynhardt, and et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases Br J Clin Pharmacol 78 2014 1315 1333
22. S. Vermeire, S. Ghosh, J. Panes, J.F. Dahlerup, A. Luegering, J. Sirotiakova, U. Strauch, G. Burgess, J. Spanton, S.W. Martin, and et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study Gut 60 2011 1068 1075